好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Long-term Follow-up of Adult Neurofibromatosis Type 1 Patients Using Whole-body MRI Demonstrates Dynamic Changes in Internal Neurofibroma Size
Neuro-oncology
S14 - Neuro-oncology (1:36 PM-1:48 PM)
004

To prospectively characterize the long-term growth behavior of internal neurofibromas (iNFs) in adult neurofibromatosis type 1 (NF1) patients using whole-body MRI (WBMRI)

iNFs affect 40-60% of NF1 patients and can cause significant morbidity and mortality. They grow more rapidly during childhood and adolescence but studies in adults are limited by their retrospective nature and follow-up time <3 years. The long-term natural history of iNFs in adults remains unknown. No guidelines exist on the need and frequency of surveillance imaging for patients. WBMRI can detect whole-body tumor burden, including iNFs.

26 adult NF1 patients who underwent WBMRI between 2007-2010 (Scan 1) underwent repeat WBMRI between 2018-2019 (Scan 2). iNFs were segmented on short tau inversion recovery (STIR) sequences and tumor volume was calculated using a computerized volumetry and three-dimensional segmentation software. Tumor growth and shrinkage were defined as volume change ≥20% over the entire study period.

Median patient age was 42 years during Scan 1 and 52 years during Scan 2. Median time between Scan 1 and 2 was 9 years. A total of 186 neurofibromas were assessed. 18% (33/186) of tumors grew by a median 68%. 59% (110/186) of tumors spontaneously decreased in volume by a median 59% without treatment. 12 new tumors developed in 10 patients. 18 tumors resolved entirely without medical or surgical intervention. 22% of patients had overall tumor growth and 39% overall tumor shrinkage. On multivariate analysis, female gender and younger age during Scan 1 were associated with tumor growth (p<0.005).

A subset of iNFs in adult NF1 patients grow significantly over a long-term period, suggesting that continued monitoring of these patients may be warranted. Surprisingly, more than half of neurofibromas shrink spontaneously without intervention. Continued patient enrollment and correlation of imaging findings with functional outcomes are underway.

Authors/Disclosures
Ina Ly, MD (Pappas Center for Neuro-Oncology)
PRESENTER
An immediate family member of Dr. Ly has received personal compensation for serving as an employee of Enanta Pharmaceuticals. Dr. Ly has received research support from Department of Defense. An immediate family member of Dr. Ly has received intellectual property interests from a discovery or technology relating to health care.
Raquel D. Thalheimer Raquel D. Thalheimer has received personal compensation for serving as an employee of Jhpeigo.
No disclosure on file
No disclosure on file
Vanessa Merker (Massachusetts General Hospital) The institution of Vanessa Merker has received research support from Children's Tumor Foundation . The institution of Vanessa Merker has received research support from NF Northeast. The institution of Vanessa Merker has received research support from Patient Centered Outcomes Research Institute. The institution of Vanessa Merker has received research support from U.S. Department of Defense . The institution of Vanessa Merker has received research support from Neurofibromatosis Therapeutic Accleration Project. Vanessa Merker has received personal compensation in the range of $10,000-$49,999 for serving as a Science Writer with Neurofibromatosis Network.
Scott R. Plotkin, MD, PhD, FAAN (Mass General Cancer Center) Dr. Plotkin has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for NFlection Therapeutics. Dr. Plotkin has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Akouos. Dr. Plotkin has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SonALAsense. Dr. Plotkin has stock in NFlection Therapeutics. Dr. Plotkin has stock in NF2 Therapeutics. Dr. Plotkin has stock in SonALAsense. Dr. Plotkin has received research support from Children's Tumor Foundation. Dr. Plotkin has received research support from Department of Defense. Dr. Plotkin has received research support from National Institutes of Health. Dr. Plotkin has received intellectual property interests from a discovery or technology relating to health care.
Justin T. Jordan, MD, MPH, FAAN (Massachusetts General Hospital) Dr. Jordan has received personal compensation for serving as an employee of City of Beverly. An immediate family member of Dr. Jordan has received personal compensation for serving as an employee of Dietitians on Demand. An immediate family member of Dr. Jordan has received personal compensation for serving as an employee of Genesis HR Solutions. Dr. Jordan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Navio Theragnostics. Dr. Jordan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Recursion Pharmaceuticals, Inc. Dr. Jordan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Shepherd Therapeutics. Dr. Jordan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion Pharmaceuticals. Dr. Jordan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Akeila Bio. Dr. Jordan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Springworks Therapeutics. Dr. Jordan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck Pharmaceuticals. Dr. Jordan has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Continental Casualty Company. Dr. Jordan has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for HennLesperance. Dr. Jordan has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Rhoades McKee. Dr. Jordan has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Wheeler Trigg O'Donnell. Dr. Jordan has stock in Navio Theragnostics. Dr. Jordan has stock in The Doctor Lounge. An immediate family member of Dr. Jordan has stock in OldGate. Dr. Jordan has stock in Akeila Bio. Dr. Jordan has stock in Shepherd Therapeutics. Dr. Jordan has stock in Khora TX. The institution of Dr. Jordan has received research support from NIH. The institution of Dr. Jordan has received research support from Department of Defense. The institution of Dr. Jordan has received research support from PCORI. Dr. Jordan has received publishing royalties from a publication relating to health care. Dr. Jordan has a non-compensated relationship as a board member with United Council for Neurologic Subspecialties that is relevant to AAN interests or activities.